Blincyto’s approval was based on results from the Phase III E1910 clinical trial, which found a significant improvement in overall survival in CD19-positive Ph-negative B-cell ALL compared with chemotherapy alone.
FDA Approves Amgen’s Blincyto for Treatment of CD19-Positive, Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
Leave a comment
